Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $3.0 million.

  • Prestige Consumer Healthcare's Capital Expenditures rose 9335.89% to $3.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.4 million, marking a year-over-year increase of 1976.42%. This contributed to the annual value of $8.2 million for FY2025, which is 1388.48% down from last year.
  • According to the latest figures from Q4 2025, Prestige Consumer Healthcare's Capital Expenditures is $3.0 million, which was up 9335.89% from $2.1 million recorded in Q3 2025.
  • Prestige Consumer Healthcare's Capital Expenditures' 5-year high stood at $4.9 million during Q1 2021, with a 5-year trough of $838000.0 in Q2 2025.
  • Its 5-year average for Capital Expenditures is $2.3 million, with a median of $2.2 million in 2021.
  • Per our database at Business Quant, Prestige Consumer Healthcare's Capital Expenditures plummeted by 6964.48% in 2021 and then skyrocketed by 9335.89% in 2025.
  • Prestige Consumer Healthcare's Capital Expenditures (Quarter) stood at $2.2 million in 2021, then decreased by 19.11% to $1.8 million in 2022, then rose by 10.7% to $2.0 million in 2023, then dropped by 21.54% to $1.6 million in 2024, then surged by 93.36% to $3.0 million in 2025.
  • Its Capital Expenditures was $3.0 million in Q4 2025, compared to $2.1 million in Q3 2025 and $838000.0 in Q2 2025.